MTOR and neoplasm: have reported that the combination of an anti-CD276 mAb with certain small-molecule inhibitors, such as the BRAF inhibitor vemurafenib, the MEK inhibitor binimetinib, the mTOR inhibitor everolimus, and the AKT inhibitor triciribidine, is effective in the treatment of metastatic melanoma, increasing the sensitivity of tumor cells to treatment and suppressing melanoma cell metastasis, proliferation, and invasion (98).